1 Min Read
April 3 (Reuters) - Alnylam Pharmaceuticals Inc
* Announced a program in partnership with Alnylam Pharmaceuticals to provide genetic testing for hereditary ATTR (HATTR) amyloidosis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.